Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 6
Submit an article Journal homepage
159
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluations

Ranpirnase (Onconase®), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy

Intae Lee University of Pennsylvania, Department of Radiology, B6 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6069, USA +1 215 609 2259; +1 215 573 2113; [email protected]
, PhD
Pages 813-827 | Published online: 14 May 2008

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sisi Li, Zhujun Wang, Xiaoping Guo, Ping Chen & Yongmin Tang. (2022) Potent anti-tumor activity of CD45RA-targeting Hm3A4-Ranpirnase against myeloid lineage leukemias. Bioengineered 13:4, pages 8631-8642.
Read now
Thomas Schirrmann, André Frenzel, Lars Linden, Beatrix Stelte-Ludwig, Jörg Willuda, Axel Harrenga, Stefan Dübel, Beate Müller-Tiemann & Mark Trautwein. (2014) Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. mAbs 6:2, pages 367-380.
Read now
Thomas Schirrmann, Jürgen Krauss, Michaela AE Arndt, Susanna M Rybak & Stefan Dübel. (2009) Targeted therapeutic RNases (ImmunoRNases). Expert Opinion on Biological Therapy 9:1, pages 79-95.
Read now

Articles from other publishers (20)

Yesuf Adem Siraj. (2022) Promises of eukaryotic ribonucleases for cancer treatment: a systematic review. Translational Medicine Communications 7:1.
Crossref
Mohammadreza Nassiri, Vinod Gopalan & Masoume Vakili-Azghandi. (2022) Modifications of Ribonucleases in Order to Enhance Cytotoxicity in Anticancer Therapy. Current Cancer Drug Targets 22:5, pages 373-387.
Crossref
Marzieh Anjomshoa & Bagher Amirheidari. (2022) Nuclease-like metalloscissors: Biomimetic candidates for cancer and bacterial and viral infections therapy. Coordination Chemistry Reviews 458, pages 214417.
Crossref
Ga Yeong Yi, Min Ju Kim, Hyo In Kim, Jinbong Park & Seung Ho Baek. (2022) Hyperthermia Treatment as a Promising Anti-Cancer Strategy: Therapeutic Targets, Perspective Mechanisms and Synergistic Combinations in Experimental Approaches. Antioxidants 11:4, pages 625.
Crossref
Mohammadreza Nassiri, Reihane Behnam-Rasouli, Masoume Vakili-Azghandi, Vinod Gopalan, Peyman Dolati & Rouhollah Nourmohammadi. (2022) Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy. Life Sciences 289, pages 120222.
Crossref
Jessica Castro, Giusy Tornillo, Gerardo Ceada, Beatriz Ramos-Neble, Marlon Bravo, Marc Ribó, Maria Vilanova, Matthew J. Smalley & Antoni Benito. (2021) A Nuclear-Directed Ribonuclease Variant Targets Cancer Stem Cells and Inhibits Migration and Invasion of Breast Cancer Cells. Cancers 13:17, pages 4350.
Crossref
Changrim Lee, Minchang Choi & J. Andrew MacKay. (2020) Live long and active: Polypeptide-mediated assembly of antibody variable fragments. Advanced Drug Delivery Reviews 167, pages 1-18.
Crossref
Sandra Jordaan, Olusiji Akinrinmade, Thomas Nachreiner, Christian Cremer, Krupa Naran, Shivan Chetty & Stefan Barth. (2018) Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells. Biomedicines 6:1, pages 28.
Crossref
Bernard Gallez, Marie-Aline Neveu, Pierre Danhier & Bénédicte F. Jordan. (2017) Manipulation of tumor oxygenation and radiosensitivity through modification of cell respiration. A critical review of approaches and imaging biomarkers for therapeutic guidance. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1858:8, pages 700-711.
Crossref
Xiuli Dan, Wenlong Liu, Jack H. Wong & Tzi B. Ng. (2016) A Ribonuclease Isolated from Wild Ganoderma Lucidum Suppressed Autophagy and Triggered Apoptosis in Colorectal Cancer Cells. Frontiers in Pharmacology 7.
Crossref
GIOU-TENG YIANG, HSIU-FENG TSAI, JER-RONG CHEN, PEI-LUN CHOU, TSAI-KUN WU, HSIAO-CHUN LIU, WEI-JUNG CHANG, LIANG-CHIH LIU, HSU-HUNG TSENG & YUNG-LUEN YU. (2014) RC-6 ribonuclease induces caspase activation, cellular senescence and neuron-like morphology in NT2 embryonal carcinoma cells. Oncology Reports 31:4, pages 1738-1744.
Crossref
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology 549 572 .
Henrike Westekemper, Michael Freistuehler, Norbert Bornfeld, Klaus-Peter Steuhl, Max Scheulen & Ralf A. Hilger. (2012) Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefe's Archive for Clinical and Experimental Ophthalmology 251:1, pages 279-284.
Crossref
Roberto E Favoni, Antonio Daga, Paolo Malatesta & Tullio Florio. (2012) Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. British Journal of Pharmacology 166:2, pages 532-553.
Crossref
C M Goparaju, J D Blasberg, S Volinia, J Palatini, S Ivanov, J S Donington, C Croce, M Carbone, H Yang & H I Pass. (2011) Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. Oncogene 30:24, pages 2767-2777.
Crossref
Carima Andrady, Surinder K Sharma & Kerry A Chester. (2011) Antibody–enzyme fusion proteins for cancer therapy. Immunotherapy 3:2, pages 193-211.
Crossref
Evandro Fei Fang & Tzi Bun Ng. (2011) Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:1, pages 65-74.
Crossref
Marc Ribó, Antoni Benito & Maria Vilanova. 2011. Ribonucleases. Ribonucleases 55 88 .
Chien-Hsing Chang, Pankaj Gupta, Rosana Michel, Meiyu Loo, Yang Wang, Thomas M. Cardillo & David M. Goldenberg. (2010) Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. Molecular Cancer Therapeutics 9:8, pages 2276-2286.
Crossref
Christian Dohmen & Manfred Ogris. 2009. Pharmaceutical Perspectives of Cancer Therapeutics. Pharmaceutical Perspectives of Cancer Therapeutics 269 295 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.